Health, pharma and science writer at Reuters. Any opinions are mine.

European project for flexible drug approvals moves up a gear

reuters.com — First face-to-face meeting to discuss a new drug April 7 * Aim is to speed initial access in small patient groups By Ben Hirschler LONDON, April 1 (Reuters) - A European project to streamline drug approvals moves up a gear next week when regulators sit down with the first company to have an experimental product assessed under a new flexible pilot scheme.

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

news.yahoo.com — By Ben Hirschler LONDON (Reuters) - Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

fecima.com — LONDON, March 23 (Reuters) - Bristol-Myers Squibb,Sanofi and Novartis have the three top newdrugs set to reach the market in 2015, among 11 products eachwith $1 billion-plus sales potential, according to a ThomsonReuters analysis. More potential blockbusters are expected to be launched thisyear than last, in an encouraging sign for the pharmaceuticalindustry, which relies on new products to replenish sales asolder medicines go off patent.

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

au.news.yahoo.com — By Ben Hirschler LONDON (Reuters) - Bristol-Myers Squibb , Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus (670 million pounds-plus) sales potential, according to a Thomson Reuters analysis.

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

uk.finance.yahoo.com — Bristol-Myers Squibb, Sanofi (LSE: 0O59.L - news) and Novartis (LSE: 0QLR.L - news) have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.

Bristol, Sanofi and Novartis drugs to shine among 2015 launches

iii.co.uk — By Ben Hirschler LONDON (Reuters) - Bristol-Myers Squibb , Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus (670 million pounds-plus) sales potential, according to a Thomson Reuters analysis.

New cancer drugs 'vastly overestimated', says contrarian analyst

reuters.com — Former top Nomura analyst Amit Roy, who now runs independent research firm Foveal, thinks sales of drugs inhibiting Programmed Death receptor (PD-1), or a related target PD-L1, will sell much less than expected.

New cancer drugs 'vastly overestimated', says contrarian analyst

reuters.com — Former top Nomura analyst Amit Roy, who now runs independent research firm Foveal, thinks sales of drugs inhibiting Programmed Death receptor (PD-1), or a related target PD-L1, will sell much less than expected.

New cancer drugs 'vastly overestimated', says contrarian analyst

businessinsider.com — By Ben Hirschler LONDON (Reuters) - A hot new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein called PD-1 is going to be big - but not nearly as big as investors think, according to a new analysis.

New cancer drugs "vastly overestimated", says contrarian analyst

reuters.com — Former top Nomura analyst Amit Roy, who now runs independent research firm Foveal, thinks sales of drugs inhibiting Programmed Death receptor (PD-1), or a related target PD-L1, will sell much less than expected.
More Articles →
Mar 31, 2015

RT @mariempowers: Wow RT @BioWorld Understaffed CFDA at the root of 18,000-application backlog, delays to market bit.ly/1NEvu6B

Mar 31, 2015

No need for #Botox to help that smile as ex-#Allergan CEO Pyott trades stock for $534M cash after company's sale bloom.bg/1HhsfOR

Mar 31, 2015

Curb your enthusiasm? New #PD-1 #cancer drugs "vastly overestimated", says contrarian analyst reut.rs/1FdQ7me $BMY $AZN $MRK $ROG

Mar 31, 2015

Call for urgent #e-cigarette controls as UK study finds one in five teens have tried vaping reut.rs/1xQCh9Q pic.twitter.com/4rfavxGoiL

Mar 30, 2015

@reutersBenHir 'Deal Monday' cont --> #UnitedHealth trumps those single-digit-billion pharma deals with $12.8B acquisition of #Catamaran

Mar 30, 2015

Turning into another 'deal Monday' in #pharma with #Teva buying #Auspex Pharma for $3.5B and #Horizon grabbing #Hyperion for $1.1B #M&A



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.

Email

For instructions on how to pitch Ben Hirschler, email reutersbenhir@muckrack.com.


Share This Profile